Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

Lymphodepleting Chemotherapy: The patient will receive a lymphodepleting regimen of fludarabine 25 mg/m2/day administered IV over 30 min for three consecutive days and a single IV dose of cyclophosphamide 900 mg/m2 administered over 1 hr on the fourth day. Administration of iC9-CAR19 T cells: Post lymphodepletion, if the patient meets eligibility criteria for cellular therapy, then will receive iC9-CAR19 T cells within 2-14 days after completing the pre-conditioning chemotherapy regimen. We will administer iC9-CAR19 post lymphodepletion at one of the following doses based on the percentage of circulating lymphoblasts prior to lymphodepletion: (1) dose of 5 x 10\^5 transduced cells/kg or (2) dose of 1 x 10\^5 transduced cells/kg. Duration of Therapy: Therapy under this compassionate use protocol involves 1 infusion of iC9-CAR19 cells. Duration of Follow-up: The patient will be followed for up to 15 years for replication-competent retrovirus evaluation or until death, whichever occurs first.